$45,168.33 speaking Payment -- Roche/Genentech to Dr. Laura Hall
Pulmonologist Receives Over $45,000 for Speaking Engagements from Roche/Genentech
This page provides a detailed analysis of a $45,168.33 speaking payment from Roche/Genentech to Dr. Laura Hall. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $45,168.33 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Roche/Genentech |
| Physician | Dr. Laura Hall |
| NPI Number | 1022309690 |
| Physician Specialty | Pulmonology |
| Location | City, VA |
| Date of Payment | 2024-04-26 |
| Related Drug/Device | Tecfidera |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Roche/Genentech made a $45.2K speaking payment to Laura Hall, a Pulmonology specialist in City, VA. The payment was associated with Tecfidera. The total payment of $45,168.33 to Dr. Laura Hall is substantial, indicating significant engagement with Roche/Genentech. The payment was for speaking engagements, suggesting Dr. Hall provided educational content related to healthcare professionals. The payment was made in April 2024, reflecting recent financial interactions between the doctor and the pharmaceutical company.
Patient Guidance: What This Payment Means for You
Patients should be aware that their doctors may receive compensation for educating other healthcare professionals about medications. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for speaking engagements can be common in specialties that involve complex or newer treatments, but this amount is on the higher end for typical speaker fees.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act's reporting requirements for payments made by manufacturers of drugs, devices, or medical supplies to physicians and teaching hospitals.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaking-fees
- speaker-program
- pulmonology
- pharmaceutical-industry
- physician-compensation
- roche-genentech
- tecfidera
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $45.2K payment for?
This was a speaking payment of $45.2K from Roche/Genentech to Laura Hall, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Tecfidera. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Laura Hall accept pharmaceutical money?
Yes, Laura Hall received this $45.2K payment from Roche/Genentech. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Laura Hall's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $45.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Pulmonology?
To compare this payment against Pulmonology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Pulmonology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Laura Hall's relationship with Roche/Genentech?
The payment amount is notably high for a single speaking engagement, suggesting multiple events or a significant role. This $45.2K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Pulmonology?
The specific drug 'Tecfidera' is mentioned, implying the speaking was likely focused on this particular medication.
What should patients do after learning about this payment?
Patients should be aware that their doctors may receive compensation for educating other healthcare professionals about medications.
What else should I know about this speaking payment?
The payment was made to an individual physician, not a group practice, highlighting direct compensation.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.